Pyxis Oncology announced that its Board of Directors has appointed Interim CEO Thomas Civik as the company's permanent Chief Executive Officer and Chairman of the Board, effective September 4, 2026. Mr. Civik has been serving as Interim CEO since February 2026. The appointment includes a new compensation package and is accompanied by other changes in board leadership.
Key Details
- Leadership Change: Thomas Civik, previously Interim CEO, is now the permanent CEO and Chairman. Former Chairman John Flavin will now serve as the Lead Independent Director.
- CEO Compensation: Mr. Civik's employment agreement includes a $710,000 annual base salary, a target bonus of 60% of his salary, a $100,000 one-time sign-on bonus, and a stock option grant to purchase 2,503,050 shares.
- Board Resignation: Dr. Santhosh Palani resigned from the Board of Directors, effective September 4, 2026, due to other professional commitments. Following his resignation, the Board size was reduced from eight to seven members.